Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2023 Filed Feb 14, 2023 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,244 | $26.17 | $32,556.72 |
DisclosureSEC source: 0001447362-23-000017 · wf-form4_167640943529038.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 120,686 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.880 to $26.515, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,489 | $26.17 | $65,139.62 |
DisclosureSEC source: 0001447362-23-000017 · wf-form4_167640943529038.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,244 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.880 to $26.515, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:22 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 698 | $27.11 | $18,920.69 |
DisclosureSEC source: 0001447362-23-000015 · wf-form4_167545930698476.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 24,393 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.830 to $27.555, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:22 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 698 | $27.11 | $18,920.69 |
DisclosureSEC source: 0001447362-23-000015 · wf-form4_167545930698476.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 24,401 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.830 to $27.555, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:22 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 698 | $27.11 | $18,920.69 |
DisclosureSEC source: 0001447362-23-000015 · wf-form4_167545930698476.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 24,401 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.830 to $27.555, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:22 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 699 | $27.11 | $18,947.79 |
DisclosureSEC source: 0001447362-23-000015 · wf-form4_167545930698476.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 24,399 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.830 to $27.555, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:22 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,398 | $27.11 | $37,895.59 |
DisclosureSEC source: 0001447362-23-000015 · wf-form4_167545930698476.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 110,825 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.830 to $27.555, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:22 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,398 | $27.11 | $37,895.59 |
DisclosureSEC source: 0001447362-23-000015 · wf-form4_167545930698476.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 121,930 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.830 to $27.555, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:22 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,795 | $27.11 | $75,764.07 |
DisclosureSEC source: 0001447362-23-000015 · wf-form4_167545930698476.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,733 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 12, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.830 to $27.555, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: On June 6, 2022, the Reporting Person transferred 130,000 shares of Castle Biosciences, Inc. common stock that was previously not reported to the DJM Grantor Retained Annuity Trust No. 4 of which the Reporting Person is trustee and beneficiary. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 375 | $22.90 | $8,587.50 |
DisclosureSEC source: 0001447362-23-000002 · wf-form4_167295726638812.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 25,093 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.60 to $23.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 375 | $22.90 | $8,587.50 |
DisclosureSEC source: 0001447362-23-000002 · wf-form4_167295726638812.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 25,097 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.60 to $23.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 375 | $22.90 | $8,587.50 |
DisclosureSEC source: 0001447362-23-000002 · wf-form4_167295726638812.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 25,097 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.60 to $23.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 375 | $22.90 | $8,587.50 |
DisclosureSEC source: 0001447362-23-000002 · wf-form4_167295726638812.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 25,098 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.60 to $23.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,750 | $22.90 | $40,075.00 |
DisclosureSEC source: 0001447362-23-000002 · wf-form4_167295726638812.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 112,224 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.60 to $23.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,875 | $22.90 | $42,937.50 |
DisclosureSEC source: 0001447362-23-000002 · wf-form4_167295726638812.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 123,328 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.60 to $23.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,833 | $22.90 | $87,775.70 |
DisclosureSEC source: 0001447362-23-000002 · wf-form4_167295726638812.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,529 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.60 to $23.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 186 | $23.41 | $4,355.00 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 14 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 25,468 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $23.090 to $23.865, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 186 | $23.41 | $4,355.00 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 25,472 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $23.090 to $23.865, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 186 | $23.41 | $4,355.00 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 25,472 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $23.090 to $23.865, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 186 | $23.41 | $4,355.00 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 25,473 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $23.090 to $23.865, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 870 | $23.41 | $20,370.18 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 113,974 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $23.090 to $23.865, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 932 | $23.41 | $21,821.85 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 125,203 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $23.090 to $23.865, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,905 | $23.41 | $44,603.67 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,362 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $23.090 to $23.865, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 189 | $22.73 | $4,296.73 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 25,654 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.090 to $23.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 189 | $22.73 | $4,296.73 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 25,658 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.090 to $23.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 189 | $22.73 | $4,296.73 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 25,658 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.090 to $23.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 189 | $22.73 | $4,296.73 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 25,659 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.090 to $23.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 880 | $22.73 | $20,005.92 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 114,844 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.090 to $23.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 943 | $22.73 | $21,438.16 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 126,135 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.090 to $23.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,928 | $22.73 | $43,831.15 |
DisclosureSEC source: 0001447362-22-000201 · wf-form4_167165747355238.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,267 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.090 to $23.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 15,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000192 · wf-form4_167096746057186.xml · derivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,273 Underlying: Common Stock · 15,425 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F10 · derivative.exercise_date: On December 10, 2021, the Reporting Person was granted 61,698 RSUs, which vest in four equal annual installments beginning on December 10, 2022. F10 · derivative.expiration_date: On December 10, 2021, the Reporting Person was granted 61,698 RSUs, which vest in four equal annual installments beginning on December 10, 2022. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 5,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000192 · wf-form4_167096746057186.xml · derivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,725 Underlying: Common Stock · 5,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: On December 10, 2020, the Reporting Person was granted 21,450 RSUs, which vest in four equal annual installments beginning on December 10, 2021. F9 · derivative.expiration_date: On December 10, 2020, the Reporting Person was granted 21,450 RSUs, which vest in four equal annual installments beginning on December 10, 2021. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 4,205 | $22.32 | $93,855.60 |
DisclosureSEC source: 0001447362-22-000192 · wf-form4_167096746057186.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,195 Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 15,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000192 · wf-form4_167096746057186.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 2,110 | $22.32 | $47,095.20 |
DisclosureSEC source: 0001447362-22-000192 · wf-form4_167096746057186.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,975 Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 5,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000192 · wf-form4_167096746057186.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 133,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000192 · wf-form4_167096746057186.xml · derivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,983 Underlying: Common Stock · 133,983 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on December 9, 2023. F8 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on December 9, 2023. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 375 | $24.79 | $9,296.25 |
DisclosureSEC source: 0001447362-22-000188 · wf-form4_167044747232046.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 25,843 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.38 to $25.26, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 375 | $24.79 | $9,296.25 |
DisclosureSEC source: 0001447362-22-000188 · wf-form4_167044747232046.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 25,847 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.38 to $25.26, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 375 | $24.79 | $9,296.25 |
DisclosureSEC source: 0001447362-22-000188 · wf-form4_167044747232046.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 25,847 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.38 to $25.26, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 375 | $24.79 | $9,296.25 |
DisclosureSEC source: 0001447362-22-000188 · wf-form4_167044747232046.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 25,848 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.38 to $25.26, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,750 | $24.79 | $43,382.50 |
DisclosureSEC source: 0001447362-22-000188 · wf-form4_167044747232046.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 115,724 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.38 to $25.26, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,875 | $24.79 | $46,481.25 |
DisclosureSEC source: 0001447362-22-000188 · wf-form4_167044747232046.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 127,078 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.38 to $25.26, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,833 | $24.79 | $95,020.07 |
DisclosureSEC source: 0001447362-22-000188 · wf-form4_167044747232046.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,723 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.38 to $25.26, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001447362-22-000186 · wf-form4_167027493591099.xml · derivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,686 Underlying: Common Stock · 10,000 shares Expires 2024-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 10,000 | $3.72 | $37,200.00 |
DisclosureSEC source: 0001447362-22-000186 · wf-form4_167027493591099.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:41 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 94 | $20.51 | $1,927.94 |
DisclosureSEC source: 0001447362-22-000180 · wf-form4_166923960476399.xml · nonDerivative · entry 14 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 26,218 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $20.32 to $20.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:41 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 94 | $20.51 | $1,927.94 |
DisclosureSEC source: 0001447362-22-000180 · wf-form4_166923960476399.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 26,222 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $20.32 to $20.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:41 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 94 | $20.51 | $1,927.94 |
DisclosureSEC source: 0001447362-22-000180 · wf-form4_166923960476399.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 26,222 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $20.32 to $20.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:41 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 96 | $20.51 | $1,968.96 |
DisclosureSEC source: 0001447362-22-000180 · wf-form4_166923960476399.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 26,223 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $20.32 to $20.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.